Literature DB >> 24402413

Author's response to 'procalcitonin in febrile neutropenia--timing is important'.

Shin Ahn1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24402413     DOI： 10.1007/s00520-013-2109-8

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  4 in total

1.  Procalcitonin-reduced sensitivity and specificity in heavily leucopenic and immunosuppressed patients.

Authors:  M Svaldi; J Hirber; A I Lanthaler; O Mayr; S Faes; E Peer; M Mitterer
Journal:  Br J Haematol       Date:  2001-10       Impact factor: 6.998

Review 2.  The role of procalcitonin in febrile neutropenic patients: review of the literature.

Authors:  Y Sakr; C Sponholz; F Tuche; F Brunkhorst; K Reinhart
Journal:  Infection       Date:  2008-08-30       Impact factor: 3.553

3.  Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia.

Authors:  Shin Ahn; Yoon-Seon Lee; Kyung Soo Lim; Jae-Lyun Lee
Journal:  Support Care Cancer       Date:  2013-03-22       Impact factor: 3.603

4.  Monitoring procalcitonin in febrile neutropenia: what is its utility for initial diagnosis of infection and reassessment in persistent fever?

Authors:  James Owen Robinson; Frédéric Lamoth; Frank Bally; Marlies Knaup; Thierry Calandra; Oscar Marchetti
Journal:  PLoS One       Date:  2011-04-25       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.